A non-randomized, open-label, single-arm, phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Cancer Chemotherapy and Pharmacology Oct 29, 2017
Sakai D, et al. - In this work, researchers investigated activity, safety, and pharmacokinetics of emibetuzumab in Asian patients with mesenchymalÂepithelial transition factor (MET) diagnostic positive, advanced gastric cancer. Findings suggested that in advanced gastric adenocarcinoma, emibetuzumab was well tolerated with limited single-agent activity.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
